(Q48650567)

13 February 2018

title

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. (English)

1 reference

13 February 2018

1 reference

1

L Klimek

1 reference

13 February 2018

Oliver Pfaar

4

object named as

O Pfaar

1 reference

13 February 2018

author name string

J Willers

2

1 reference

13 February 2018

A Hammann-Haenni

3

1 reference

13 February 2018

H Stocker

5

1 reference

13 February 2018

P Mueller

6

1 reference

13 February 2018

W A Renner

7

1 reference

13 February 2018

M F Bachmann

8

1 reference

13 February 2018

publication date

14 June 2011

1 reference

13 February 2018

Clinical & Experimental Allergy

published in

1 reference

13 February 2018

volume

41

1 reference

13 February 2018

issue

9

1 reference

13 February 2018

page(s)

1305-1312

1 reference

13 February 2018

Long-term clinical efficacy of grass-pollen immunotherapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Long-term efficacy of preseasonal grass pollen immunotherapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Immunotherapeutic targeting of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Oligonucleotide sequences required for natural killer cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

21 January 2018

Allergen Immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2011.03783.X

10.1111/J.1365-2222.2011.03783.X

21 January 2018

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018